InDex Pharmaceuticals presents at the Introduce Investor Days

May 23, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at the Introduce Investor Days at Haymarket by Scandic in Stockholm on May 27 at 9.30 CET.

The event is hosted by ABG Sundal Collier and is open for both private and institutional investors. The presentation will also be livestreamed and can be followed at www.introduce.se.


For more information:
Peter Zerhouni, CEO
P
hone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com 


InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Stockholm. Redeye AB with email address certifiedadviser@redeye.se and phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit www.indexpharma.com.

Publication
The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on May 23, 2019.